
Gifting Made Simple
Give the Gift of ChoiceClick below to purchase a Pine Centre eGift Card that can be used at participating retailers at Pine Centre.Purchase HereHome
ENHANZE® Drug Delivery Technology: Advancing Subcutaneous Drug Delivery using Recombinant Human Hyaluronidase PH20
Coles
Loading Inventory...
ENHANZE® Drug Delivery Technology: Advancing Subcutaneous Drug Delivery using Recombinant Human Hyaluronidase PH20
By None
Current price: $0.99

Coles
ENHANZE® Drug Delivery Technology: Advancing Subcutaneous Drug Delivery using Recombinant Human Hyaluronidase PH20
By None
Current price: $0.99
Loading Inventory...
Size: Kobo eBook (2025)
*Product information and pricing may vary - to confirm current pricing, availability, shipping, and return information please contact Coles. In the event of a pricing discrepancy, the retailer's price will apply.
'ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20' provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology of hyaluronan and hyaluronidases in the SC space, and a comprehensive overview on the history of hyaluronidases and the development of recombinant human hyaluronidase PH20 (rHuPH20). Current applications of rHuPH20 as well as approved biotherapeutics utilizing HuPH20-facilitated SC drug delivery are summarized, and the underlying non-clinical and clinical development approaches are introduced as a basis for future application to biologics in various disease areas.
'ENHANZE® drug delivery technology: Advancing subcutaneous drug delivery using recombinant human hyaluronidase PH20' provides readers with in-depth information on the potential benefits and challenges of subcutaneous (SC) drug delivery, the biology of hyaluronan and hyaluronidases in the SC space, and a comprehensive overview on the history of hyaluronidases and the development of recombinant human hyaluronidase PH20 (rHuPH20). Current applications of rHuPH20 as well as approved biotherapeutics utilizing HuPH20-facilitated SC drug delivery are summarized, and the underlying non-clinical and clinical development approaches are introduced as a basis for future application to biologics in various disease areas.



















